Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare providers to prescribe weight loss treatments from Eli Lilly.
The telehealth firm said clinicians using its platform can now issue prescriptions for Zepbound vials, KwikPen, and Foundayo, which can be fulfilled through the LillyDirect pharmacy. The service includes access to self-pay pricing options for Hims & Hers customers and enables licensed providers to connect patients with FDA-approved GLP-1 therapies.
Broader push into GLP-1 treatments
The move builds on a prior announcement last month, when Hims & Hers partnered with Novo Nordisk to offer access to Wegovy injections and oral treatments.
The company said these initiatives reflect a broader strategic shift in its U.S. weight loss segment, driven by growing demand and evolving market dynamics around GLP-1 medications.
Expanded care offering for members
Hims & Hers noted that its weight loss program includes a range of support services, such as 24/7 access to care teams, personalized nutrition plans, regular clinical follow-ups, and peer support through its Weight Loss community.
Focus on personalized treatment access
The company added that its goal is to give users access to a wide selection of treatment options, combined with a comprehensive care experience tailored to individual medical history, preferences, and health goals.